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COST-EFFECTIVENESS OF PRAMIPEXOLE IN 
PARKINSON’S DISEASE IN THREE COUNTRIES
Hoerger T1, Bala M2, Greer M3, Rowland C4
1Research Triangle Institute, Research Triangle Park, NC, US; 
2Centocor, Inc., Malvern, PA, US; 3Boehringer Ingelheim 
Pharmaceuticals, Inc., Ridgefield, CT, US; 4Pharmacia & Upjohn, 
Kalamazoo, MI, US
OBJECTIVES: A pharmacoeconomic model is used to es-
timate the costs and cost-effectiveness of treating Parkin-
son’s disease patients with pramipexole in Canada, Ger-
many, and Sweden.
METHODS: We developed a cost-effectiveness model
that linked Unified Parkinson’s Disease Rating Scale
(UPDRS) Part II (ADL) and III (Motor) scores to disease
progression, costs, and quality-adjusted life years (QALYs).
Data were obtained from clinical trials, literature review,
and a survey of 193 patients’ resource use and health util-
ity. Country-specific data on treatment patterns were col-
lected using panels of physician experts in each country.
Cost and QALY estimates from the model were used to
estimate the incremental cost-effectiveness of pramipex-
ole relative to baseline treatment. Separate analyses were
performed for early and advanced Parkinson’s patients.
Extensive sensitivity analyses were performed.
RESULTS: In Canada and Germany, treatment with
pramipexole has higher costs but is more effective than
baseline treatment. In Sweden, treatment with pramipexole
has lower costs and is more effective than baseline treat-
ment. The incremental cost-effectiveness ratios for early
patients in Canada, Germany, and Sweden are $CDN
28,097, DM 26,780, and -SEK 41,161, respectively (in
1997 currency). For advanced patients, the corresponding
ratios are $CDN 25,090, DM 49,168, and -SEK 27,386.
These ratios are lower than the cost-effectiveness ratios of
many widely used medical treatments. 
CONCLUSIONS: Subject to the inherent limitations of
modeling chronic disease progression and subsequent
health utility and costs, the results indicate that prami-
pexole is a cost-effective treatment for early and ad-
vanced Parkinson’s disease patients in Canada, Germany,
and Sweden.
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CHARACTERISTICS OF CHRONIC AIRWAY 
DISEASE PATIENTS STARTED ON NEBULIZED 
IPRATROPIUM SOLUTION
LeLorier J1, Blais L1, Castilloux A-M1, Renzi P1, Miller B2
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BACKGROUND: There has been an important increase
in the use of nebulized ipratropium solution (NIS) in the
ambulatory treatment of elderly patients with chronic air-
way disease. Since these are relatively expensive medica-
tions, it is important to define the characteristics and the
natural history of the patients who are started on this
therapy and compare them with those of the patients
started on ipratropium metered dose inhalers (IMDI) or
oral theophylline (OT).
METHODS: The Quebec health insurance program
(RAMQ) database was used for the study. The index date
was the first dispensation of NIS (n  761), IMDI (n 
3870), or OT (n  10355). The consumption of drugs
and medical services was measured during the 12 months
before the index date.
RESULTS: At the time therapy was initiated, patients
started on NIS had had more hospitalization days for
chronic airway disease (NIS: 2.97, IMDI: 0.92, OT:
0.12). They were also much heavier users of beta-agonists
(NIS: 13.53, IMDI: 4.9, OT: 0.11) and inhaled cortico-
steroids (NIS: 4.63, IMDI: 2.1, OT: 0.37). The fact that
patients started on NIS had a more advanced form of
chronic airway disease was confirmed by their much
higher mortality rates (percent and 95% CI) during the
12 months following their index date (NIS: 17.2 [14.3–
20.1], IMDI: 8.3 [7.5–9.1], OT: 4.9 [4.6–5.3]).
CONCLUSION: Patients are started on NIS when they
have reached a very advanced form of their disease, as
shown by their high mortality rates and extremely heavy
use of beta-agonists.
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THE EFFECT OF AGE ON COST-EFFECTIVENESS 
IN THE TREATMENT OF MODERATE ASTHMA
Kielhorn A, Behrens M
Glaxo Wellcome GmbH & Co., Hamburg, Germany
OBJECTIVE: The aim of this work is to identify the ef-
fect of age on cost-effectiveness in the treatment of mod-
erate asthma patients with inhaled corticosteroids.
METHODS: The cost-effectiveness analysis was con-
ducted as a retrospective analysis of clinical trial data.
The data of one open and one double-blind multicenter,
parallel group study comparing the efficacy of Flutica-
sone and Flunisolide were pooled. The pooled intent-to-
treat (ITT) group consisted of 308 patients. Because of
the retrospective nature of the study, only the costs of
treatment medication and of concomitant medication
were included. No hospital admissions occurred. The ad-
verse event costs were identified as negligible and there-
fore omitted. Because physicians’ visits were protocol
driven, they were also excluded. Effectiveness (success-
fully treated patients) was defined by an increase in peak
flow of 5% or more. Total treatment costs for each age
group were calculated and divided over the number of
patients fulfilling the effectiveness criterion.
RESULTS: Total average daily treatment costs per pa-
tient were DM 4.58 (sd  DM 1.61). The average cost-
effectiveness ratio per successfully treated patient was
DM 7.84 (sd  DM 1.72). The cost-effectiveness ratios
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were positively correlated to age (p  0.05). This effect
was caused by slightly rising total treatment costs over
age and a declining number of patients fulfilling the effec-
tiveness criterion.
CONCLUSION: Cost-effectiveness ratios are positively
correlated to age in the treatment of moderate asthmatics.
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A HOSPITAL’S PERSPECTIVE:
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OBJECTIVE: To investigate the feasibility of different
methodologies for a prospective matched-pair design study
on the incremental daily cost of disease for patients with
nosocomial pneumonia (NP) from a hospital’s perspective. 
METHOD: Adult patients newly admitted to three ICUs
with 3 days of hospitalization and without preexisting
pneumonia were followed up daily until discharge (maxi-
mum 30 days). Any new onset of NP was registered. Gen-
der, age, diagnosis at admission, underlying disease, surgery,
ward, further diagnosis, Apache II-Score, and Kropec-
Pneumonia-Risc-Score were preselected as matching cri-
teria for controls. Consumed resources were documented
daily. Costs were calculated by two methods: a combined
bottom-up approach (resource consumption of drugs,
blood products, diagnostics, other medical materials) and
top-down approach (proportionate cost based on ac-
counting figures by ward for all other costs). Alterna-
tively, all costs were calculated top-down based on ad-
ministrative data.
RESULTS: In 25 days 112 patients were registered; 50
met all study criteria, of whom 3 developed nosocomial
pneumonia. Matching was possible only on gender, age,
reason for admission (eight categories), ward, hospital
days until onset, immunosuppressive and respiratory sta-
tus. The average incremental daily cost for patients with
NP was DM 440  140%. Both costing methods led to
similar results (2% difference). The first method required
significantly more time for data collection. The sample
size for a study, given that the 95% confidence range of
cost equals the mean of the incremental cost (33%), is 40
patients with NP, plus an adequate number of controls.
CONCLUSION: The approach involving some bottom-
up data is not feasible for a full study. The top-down only
approach more efficiently leads to quite similar results.
For reconfirmation, a larger sample size would be neces-
sary. However, time saved accompanies a loss in preci-
sion. In the future, more wards, with preferably long av-
erage stays, should be included to efficiently document
more cases of nosocomial pneumonia.
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Smoking is a high-risk behavior affecting the health and
economic welfare of a society. Thus it is important to
quantify the economic burden of the negative impact due
to smoking in Germany. Approximately 33.4% of the
male and 20.4% of the female German population are
current smokers.
OBJECTIVE: This study investigates the healthcare costs
of smoking on the six most frequent diseases associated
with the inhalation of tobacco smoke: lung cancer (ICD
162; attributable to smoking, 89%), cancer of the mouth
and larynx (ICD 140–149, 161; 85%), chronic obstruc-
tive pulmonary disease (COPD, ICD 490–491; 73%),
coronary artery disease (ICD 410–414; 35%), stroke
(ICD 434–438; 28%), and atherosclerotic occlusive dis-
ease (ICD 440; 28%).
METHODS: A data search was carried out using several
literature databases including MedLine and DIMDI, as
well as health insurance and Federal Institute of Statistics
databases.
RESULTS: Total smoking-related costs for these diseases
in Germany are 31.4  109 DM, equivalent to 49% of the
overall costs. In detail (1995 figures), smoking-related lung
cancer contributes 4.8  109 DM, cancer of the mouth and
larynx 2.5  109 DM, COPD 11.3  109 DM, coronary
artery disease 8.6  109 DM, stroke 3.1  109 DM, and
atherosclerotic occlusive disease 1.1  109 DM.
CONCLUSION: The conservative calculation of the eco-
nomic impact based on only 6 of more than 25 diseases
known to be associated with smoking results already in a
burden of more than 31 billion DM. Further detailed
analyses are needed to better quantify the health eco-
nomic impact.
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COST-EFFECTIVENESS ANALYSIS OF A FIXED 
COMBINATION (DICLOFENAC 
 
MISOPROSTOL) IN THE PREVENTION OF 
GASTROPATHY IN ARTHRITIS PATIENTS
IN BELGIUM
Annemans L, Vanoverbeke N, Van Rompay W
HEDM, Mechelen, Belgium
OBJECTIVES: To calculate the costs and cost-effective-
ness of a fixed combination of diclofenac 75 mg 
 miso-
prostol 200 g bid compared with diclofenac 75 mg bid
in preventing gastropathy in Belgium.
METHODS: We developed a new decision-analytical
model comparing diclofenac 
 misoprostol (DM) to di-
clofenac (D), taking into account clinical data on gastrop-
